Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
piperazine derivative |
| gptkbp:CASNumber |
6640-24-0
|
| gptkbp:chemicalFormula |
C10H13ClN2
|
| gptkbp:drugClass |
recreational drug
serotonin receptor agonist |
| gptkbp:has_parent_compound |
phenylpiperazine
|
| gptkbp:hasInChIKey |
JZKJQQUUPWQZHK-UHFFFAOYSA-N
|
| gptkbp:hasSMILES |
Clc1cccc(c1)N2CCNCC2
|
| https://www.w3.org/2000/01/rdf-schema#label |
meta-chlorophenylpiperazine
|
| gptkbp:IUPACName |
gptkb:1-(3-chlorophenyl)piperazine
|
| gptkbp:legalStatus |
controlled substance in some countries
|
| gptkbp:meltingPoint |
242–244 °C
|
| gptkbp:metabolism |
gptkb:nefazodone
gptkb:trazodone |
| gptkbp:molecularWeight |
196.68 g/mol
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
anxiety headache insomnia hallucinations |
| gptkbp:synonym |
gptkb:mCPP
|
| gptkbp:usedFor |
recreational drug
research chemical |
| gptkbp:bfsParent |
gptkb:mCPP
|
| gptkbp:bfsLayer |
8
|